Woo Jennifer S, Alberti Michael O, Tirado Carlos A
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, 1010 Veteran Ave, 2nd Floor, room 2212 F, Los Angeles, CA 90024, USA.
Exp Hematol Oncol. 2014 Jun 13;3:16. doi: 10.1186/2162-3619-3-16. eCollection 2014.
In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent childhood hematological malignancy, as well as the leading cause of childhood cancer-related mortality. Advances in cytogenetics utilizing array-based technologies and next-generation sequencing (NGS) techniques have revealed exciting insights into the genetic basis of this disease, with the hopes of developing individualized treatment plans for affected children. In this comprehensive review, we discuss our current understanding of childhood (pediatric) B-ALL and highlight the most recent genetic advances and their therapeutic implications.
在儿科人群中，B 淋巴细胞急性淋巴细胞白血病（B-ALL）是最常见的儿童血液系统恶性肿瘤，也是儿童癌症相关死亡的主要原因。利用基于阵列的技术和下一代测序（NGS）技术的细胞遗传学进展，为该疾病的遗传基础揭示了令人兴奋的见解，有望为患病儿童制定个性化治疗方案。在这篇全面综述中，我们讨论了目前对儿童（儿科）B-ALL 的认识，并强调了最新的遗传学进展及其治疗意义。
